Introduction
============

One of the major obstacles to improving breast cancer treatment is the lack of a sensitive and specific assay with which to evaluate the effect of therapy in the adjuvant setting and in metastatic disease. It has been shown that cells can be shed from the tumour at all stages of disease and that these cells may remain in the patient\'s circulation for lengthy periods after initial treatment of the primary tumour \[[@B1],[@B2]\], but in a proportion of patients these can eventually develop into metastases. Numbers of such cells vary depending on the method and sample, from very few if bone marrow mononuclear cells are analyzed (median 2 per 2 × 10^6^in breast cancer patients) \[[@B3]\] to between 5 and 20,000 cells per 7.5 ml blood sample (corresponding to 6 to 25,000 cells per 2 × 10^6^mononuclear blood cells) \[[@B4]\] in metastatic breast cancer. Using magnetic bead enrichment and microfluorimetry \[[@B5]\] in lung cancer patients after surgery we had identified numbers of cells \[[@B6]\] similar to those reported by Cristofanilli and coworkers \[[@B4]\]. Recently, we improved this method to avoid cell loss resulting from enrichment procedures and centrifugation, and we were able to detect even higher numbers of epithelial cells in patients with malignant epithelial tumours (between 50/ml and 300,000/ml in more than 90% of patients) \[[@B7]\]. The question then arises regarding whether these epithelial cells, which are detectable in such high numbers, are indeed tumour cells. Preoperative chemotherapy in breast cancer patients \[[@B8],[@B9]\] provides a model in which to address this question. In these patients the initial size of the tumour, as analyzed by magnetic resonance imaging before therapy, can be compared with the size determined by pathological analysis of the remaining tumour tissue after therapy at surgery \[[@B10]\]. This reduction in size can be correlated to the reduction in numbers of blood epithelial cells.

Materials and methods
=====================

In order to measure the reduction in circulating epithelial cells induced by neoadjuvant chemotherapy, we monitored epithelial cells before each therapy cycle in 30 patients with breast cancer treated with two different neoadjuvant chemotherapy schedules \[[@B11],[@B12]\]. Only the first three (dose intensified) epirubicin or four epirubicin/cyclophosphamide cycles of the regimen were considered in the analysis because measurement of the numbers of cells during the following cycles was confounded by release of cells from disintegrating tumour tissue (Camara O and coworkers, unpublished data).

Once informed consent had been obtained from all participants, as required for ethics committee approval, peripheral blood anticoagulated with EDTA was drawn before the start of therapy and before each of the following therapy cycles. As a control, blood from 25 patients with nonepithelial haematological malignancies in different stages of disease (seven with chronic myelogenous leukaemia (five in clinical remission and two who had relapsed), five with acute lymphocytic leukemia (two in clinical remission), five with acute myelogenous leukemia (two in clinical remission after allogeneic stem cell transplantation) and eight patients with plasmocytoma (five in clinical remission after autologous stem cell transplantation and three who had relapsed)) was also analyzed for circulating cell staining with the antiepithelial antibody. First, red blood cells were lysed using ammonium chloride, which was followed by a single centrifugation step. Then, the pellet of white cells was collected (in accordance with a previously described approach \[[@B7]\]) and incubated with FITC-conjugated mouse anti-human epithelial antibody (HEA; Miltenyi Bergisch Gladbach, Germany), and live cells in suspension were applied to a poly-L-lysine treated slide, which was analyzed using a Laser Scanning Cytometer^®^(Compucyte Corporation, Cambridge, MA, USA) \[[@B11]\]. This method, termed MAINTRAC^®^analysis, enables relocation of cells for visual examination and quantification, and for taking fluoromicrographs. Typical cells (green fluorescence, exclusively located at the surface, indicative for viability, often forming caps) are shown in Fig. [1](#F1){ref-type="fig"}; note that the right-most cell is counter-stained for the oestrogen receptor.

Results
=======

In previous experiments \[[@B7]\] we performed combination staining with anti-CD45-PE and restaining with cytokeratin, and found that CD45^+^blood cells could easily be discriminated from epithelial cells, and that all cells staining with anti-EpCAM (epithelial cell specific adhesion molecule) also stained with cytokeratin. Nonspecific staining with anti-EpCAM can occur when one is using fixed cells and intracellular staining, but this was not a problem when live cells were analyzed, which were defined as cells exhibiting exclusive surface staining. In the previous study \[[@B7]\] no live epithelial antigen positive cells were detected in 97% of healthy donors aged between 17 and 75 years.

In none of the patients with haematological malignancies, whether full blown, in complete remission with regenerating haematopoiesis, or in relapse, could we detect cells staining with the HEA antibody. In breast cancer patients assigned to neoadjuvant treatment, live epithelial cells were detected in all patients before the start of therapy, with pretherapy numbers between 600 and 273,150 cells/ml (mean 11,876 cells/ml). Duplicate analyses differed by less than 10%. Typical longitudinal analyses (normalized to pretherapy values, which were set at 100%) during the three epirubicin cycles are shown for 14 patients in Fig. [2a](#F2){ref-type="fig"}. The decrease in the number of circulating tumour cells (CTCs) from different breast cancer patients varied, and the difference was up to several hundred-fold, indicating that cells from individual patients respond differently to the same therapy schedule. The same was true for the 16 patients treated with the epirubicin/cyclophosphamid schedule (not shown).

Reductions in cell numbers (the nadir of circulating cell numbers was used) were strongly correlated (R^2^= 0.97) with final tumour reduction in the patients receiving dose-intensified epirubicin (calculated as the difference between pretherapy volume (determined using magnetic resonance) and remaining tumour volume at surgery (determined by the pathologist); 8/14 patients underwent surgery; Fig. [2b](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}).

The epirubicin/cyclophosphamide group was further divided into patients who did not receive subsequent herceptin therapy (7/8 underwent surgery) and HER2/neu-positive patients who received herceptin treatment after chemotherapy (6/8 underwent surgery; Table [1](#T1){ref-type="table"}). The correlation coefficients between CTC reduction with initial chemotherapy and tumour volume reduction was R^2^= 0.79 in the chemotherapy-only group and R^2^= 0.059 in the group in which chemotherapy was followed by herceptin treatment. It should be noted that measurements were performed during epirubicin/cyclophosphamide cycles only; this is because later analyses may be perturbed by release of cells from decaying tumour tissue and therefore were not included. Thus, although the circulating epithelial cells in the HER2/neu-positive group did not respond adequately to epirubicin/cyclophosphamide, tumours frequently exhibited a good response at the end of therapy after application of herceptin. The lack of correlation in the herceptin treatment group indicates that subsequent antibody treatment contributes to tumour reduction in a different manner, which is not reflected in the initial response of CTCs to chemotherapy.

Discussion
==========

In patients with breast cancer we found that the first few courses of neoadjuvant chemotherapy had identical influence on CTC numbers, and that therapy reduced CTCs in the same way as it affected the tumour *per se*. Because circulating epithelial cells detected using our approach respond to chemotherapy in the same way as the tumour does, it is likely that these cells in peripheral blood of untreated breast cancer patients stem from the tumour. Also, the strong correlation between the reduction in CTCs with chemotherapy and the final reduction in size of the tumour indicates that monitoring of CTCs, even during the first cycles of therapy, predicts whether the tumour ultimately will respond adequately to this therapy \[[@B13]\] (the course of which lasts almost half a year). Unnecessary toxicity during neoadjuvant therapy could therefore be avoided by discontinuing ineffective therapy.

In contrast, in the HER2/neu-positive group circulating epithelial cells did not respond adequately to chemotherapy, but a large proportion of the tumours in ultimately exhibited complete response to the entire therapy (including chemotherapy and antibody therapy). This is in good agreement with the known reduced responsiveness of HER2/neu-positive tumour cells to chemotherapy (other than with subsequent antibody therapy \[[@B14]\], during which analyses were not performed). Importantly, such analyses conducted during adjuvant treatment, for which no other marker is yet available, could -- for the first time -- help in determining immediately whether the applied therapy is effective.

The significance of circulating epithelial cells in tumour patients is still unclear. It is not known how long such cells survive \[[@B2]\] or to what extent they are able to form metastases. It appears that the potential to grow into metastases may be restricted to a small fraction \[[@B15]\] of \'stem cells\' \[[@B16]\]. Therefore, it may not be the simple number of CTCs but rather their behaviour (decrease or increase) during the course of disease that may predict patient outcome.

Conclusion
==========

The method presented here permits easy, rapid, reliable and reproducible repeated quantification of epithelial cells in peripheral blood, and could serve as a tool for real-time monitoring of therapy *in vivo*. This will become especially valuable in the adjuvant setting, where therapy has until now been given without any ability to measure the efficacy of treatment.
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![Fluorimetric analysis, relocalization and fluoromicrograph of individual circulating tumour cells. Shown are the procedure for quantification and visual control (1 hour for cell preparation and analysis) and three typical viable circulating tumour cells (green fluorescing cap). One cell is also stained for oestrogen receptor (orange fluorescence).](bcr1328-1){#F1}

![Changes in circulating tumour cell numbers. **(a)**Fourteen typical courses of changes in cell numbers in breast cancer patients monitored during neoadjuvant (primary) therapy. **(b)**Comparison of the response of circulating tumour cells during the first three (or four) therapy cycles versus tumour reduction in the therapy regimen without herceptin (thick lines) and the regimen including herceptin (thin line).](bcr1328-2){#F2}
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Correlation between reduction in tumour size and reduction in circulating tumour cells with treatment

  Patient group                                                     Tumour size before treatment (mm)   Tumour size at surgery (mm)                                    Fold reduction in circulating cell numbers
  ----------------------------------------------------------------- ----------------------------------- -------------------------------------------------------------- --------------------------------------------
  Patients receiving dose-dense epirubicin                          25 × 25 × 25                        12 × 12 × 12                                                   9.09
                                                                    25 × 20 × 25                        9 × 12 × 8 + small remnant tumour structures                   14.70
                                                                    70 × 50 × 25                        70 × 50 × 20                                                   1.00
                                                                    85 × 85 × 85                        38 × 26 × 22                                                   666.67
                                                                    50 × 50 × 50                        0                                                              111.11
                                                                    60 × 60 × 60                        ND                                                             16.00
                                                                    35 × 35 × 20                        11 × 11 × 11                                                   31.00
                                                                    25 × 25 × 25                        20 × 20 × 20                                                   3.80
                                                                                                                                                                       
  Patients receving epirubicin/cyclophosphamide without herceptin   22 × 15 × 28                        13 × 10 × 8                                                    3.70
                                                                    50 × 50 × 50                        15 × 10 × 12                                                   50.00
                                                                    25 × 25 × 25 + DCIS                 7 × 7 × 7 + small remnant tumour structures                    18.18
                                                                    40 × 30 × 30                        27 × 27 × 27                                                   3.68
                                                                    36 × 40 × 26                        15 × 15                                                        46.00
                                                                    50 × 30                             25 × 35 × 17                                                   0.80
                                                                    15 × 11 × 13 and 8 × 9 × 8          17 × 15 × 9                                                    23.00
                                                                                                                                                                       
  Patients receiving epirubicin/cyclophosphamide with herceptin     80 × 70 × 70                        Not yet available                                              
                                                                    50 × 30 × 40                        0                                                              1.40
                                                                    20 × 32 × 20                        5 × 5 × 5                                                      0.53
                                                                    38 × 26 × 37                        Right: 26 × 17; left: 17 × 13 and 16 × 9 and 7 × 6 and 3 × 5   37.60
                                                                    20 × 24 × 20                        0                                                              9.20
                                                                    32 × 18 × 20                        0                                                              0.50
                                                                    20 × 15 × 20                        0                                                              71.67

Tumour size (as determined using magnetic resonance) before initiation of treatment and tumour size at surgery (as determined by the pathologist) and reduction in circulating epithelial cells. Patients received dose-dense epirubicin (three cycles), epirubicin/cyclophosphamide (four cycles) without subsequent herceptin treatment, or epirubicin/cyclophosphamide (four cycles) and subsequent herceptin. DCIS, ductal carcinoma *in situ*; ND, not determined.
